Connor, Clark & Lunn Investment Management Ltd. Relmada Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$3.1 - $6.8 $107,678 - $236,198	-34,735 Reduced 56.79%	26,426 $122,000
Q4 2023 Feb 09, 2024	SELL	$2.45 - $4.22 $63,680 - $109,686	-25,992 Reduced 29.82%	61,161 $253,000
Q3 2023 Nov 13, 2023	SELL	$2.48 - $3.79 $43,057 - $65,801	-17,362 Reduced 16.61%	87,153 $261,000
Q2 2023 Aug 10, 2023	SELL	$2.22 - $3.54 $12,085 - $19,271	-5,444 Reduced 4.95%	104,515 $257,000
Q1 2023 May 09, 2023	SELL	$2.24 - $4.76 $19,470 - $41,373	-8,692 Reduced 7.33%	109,959 $248,000
Q4 2022 Feb 10, 2023	BUY	$2.17 - $35.84 $182,963 - $3.02 Million	84,315 Added 245.56%	118,651 $414,000
Q3 2022 Nov 10, 2022	BUY	$18.3 - $37.02 $628,348 - $1.27 Million	34,336 New	34,336 $1.27 Million

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account